Oral Protein Degrader Candidate Selector
Catalent’s ProteoSuite Oral platform is designed for optimized selection of orally developable targeted protein degrader candidates.
Catalent’s ProteoSuite Oral platform is designed for optimized selection of orally developable targeted protein degrader (TPD) candidates for advancement into clinical trials. Factors considered by the platform include molecular descriptors, physicochemical characterizations, drug metabolism and pharmacokinetics data, and physiologically based pharmacokinetic modeling.
The ProteoSuite aims to improve the likelihood of oral TPD development success by utilizing specialized assays and developability models that systematically evaluate oral drug candidates and enable quick, effective shortlisting of potential candidates. The platform includes integrated potent handling capabilities from clinical development and supply to commercial.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
